Selling, General, and Administrative Costs: Pharming Group N.V. vs Lantheus Holdings, Inc.

SG&A Expenses: Lantheus vs. Pharming, 2014-2023

__timestampLantheus Holdings, Inc.Pharming Group N.V.
Wednesday, January 1, 2014724290004042025
Thursday, January 1, 2015786340005279557
Friday, January 1, 2016753740008073913
Sunday, January 1, 20179215700044864073
Monday, January 1, 20189332600053488904
Tuesday, January 1, 201910313200065896361
Wednesday, January 1, 202011017100069968267
Friday, January 1, 202121881700092047281
Saturday, January 1, 2022233827000131819000
Sunday, January 1, 202326719400087501000
Loading chart...

Unlocking the unknown

A Comparative Analysis of SG&A Expenses in the Pharmaceutical Sector

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Pharming Group N.V. and Lantheus Holdings, Inc., from 2014 to 2023. Over this period, Lantheus Holdings, Inc. consistently outpaced Pharming Group N.V. in SG&A spending, with a notable increase of approximately 270% from 2014 to 2023. In contrast, Pharming Group N.V. saw a more modest rise of around 210% in the same timeframe. The year 2022 marked a peak for Pharming Group N.V., with expenses reaching their highest, while Lantheus Holdings, Inc. continued its upward trajectory into 2023. This trend highlights Lantheus's aggressive market strategies and expansion efforts, while Pharming Group N.V. maintains a more conservative approach.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025